Disease‐modifying antirheumatic drugs
Identifieur interne : 000D58 ( Istex/Corpus ); précédent : 000D57; suivant : 000D59Disease‐modifying antirheumatic drugs
Auteurs : Vera J. Stecher ; John A. Carlson ; Kevin M. Connolly ; Denis M. BaileySource :
- Medicinal Research Reviews [ 0198-6325 ] ; 1985-07.
English descriptors
- Teeft :
- Acylator phenotype, Adverse effects, Amer, American association, Antibody production, Antimalarial, Antirheumatic, Antirheumatic drugs, Arthritic rats, Arthritis, Arthritis rheum, Autoimmune disease, Bailey, Biochemical variables, Blood cells, Cancer patients, Carlson, Cell antibody production, Cell number, Cell response, Chloroquine, Clin, Clinical improvement, Clinical trials, Clinical variables, Clinics committee, Connolly, Control group, Cotton pellet granuloma, Crockson, Daily dose, Disease remission, Dmard, Dmard therapy, Dmards, Drug therapy, Drug treatment, Early stages, Effector, Effector cell function, Effector cells, Erythrocyte sedimentation rate, Experimental diet, Experimental group, Gold salts, Goldstein, Greater benefit, Haptene formation, Helper, Helper cell function, Helper cell proliferation, Helper cells, High incidence, High levels, Human model, Hydroxychloroquine, Ideal drug, Immune, Immune dysfunction, Immune response, Immune system, Immunol, Immunological, Immunological dysfunction, Immunomodulating activity, Immunomodulating drug therapy, Immunomodulatory activity, Inflammation, Inflammation research, Injectable gold, Joint destruction, Large numbers, Lupus erythematosus, Lymphocyte, Macrophage, Mcconkey, Medicinal chemistry, Normal host, Normal levels, Nsaid, Nutritional therapy, Patient populations, Percent gold, Peripheral blood, Peripheral blood leukocytes, Possible mechanisms, Previous examples, Proc, Prostaglandin, Raven press, Research institute, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatol, Risk ratio, Scand, Side effects, Significant decrease, Splenic lymphocytes, Stecher, Sulphasalazine, Suppl, Suppressor, Suppressor cell, Suppressor cell proliferation, Suppressor cells, Suppressor response, Symptomatic relief, Therapeutic agent.
Url:
DOI: 10.1002/med.2610050305
Links to Exploration step
ISTEX:1A3F5E9D74FA16125C32AD312F886727A964F8D4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease‐modifying antirheumatic drugs</title><author><name sortKey="Stecher, Vera J" sort="Stecher, Vera J" uniqKey="Stecher V" first="Vera J." last="Stecher">Vera J. Stecher</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Carlson, John A" sort="Carlson, John A" uniqKey="Carlson J" first="John A." last="Carlson">John A. Carlson</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Connolly, Kevin M" sort="Connolly, Kevin M" uniqKey="Connolly K" first="Kevin M." last="Connolly">Kevin M. Connolly</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Bailey, Denis M" sort="Bailey, Denis M" uniqKey="Bailey D" first="Denis M." last="Bailey">Denis M. Bailey</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1A3F5E9D74FA16125C32AD312F886727A964F8D4</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1002/med.2610050305</idno><idno type="url">https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D58</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Disease‐modifying antirheumatic drugs</title><author><name sortKey="Stecher, Vera J" sort="Stecher, Vera J" uniqKey="Stecher V" first="Vera J." last="Stecher">Vera J. Stecher</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Carlson, John A" sort="Carlson, John A" uniqKey="Carlson J" first="John A." last="Carlson">John A. Carlson</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Connolly, Kevin M" sort="Connolly, Kevin M" uniqKey="Connolly K" first="Kevin M." last="Connolly">Kevin M. Connolly</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author><author><name sortKey="Bailey, Denis M" sort="Bailey, Denis M" uniqKey="Bailey D" first="Denis M." last="Bailey">Denis M. Bailey</name><affiliation><mods:affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="371">371</biblScope><biblScope unit="page" to="390">390</biblScope><biblScope unit="page-count">20</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1985-07">1985-07</date></imprint><idno type="ISSN">0198-6325</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acylator phenotype</term><term>Adverse effects</term><term>Amer</term><term>American association</term><term>Antibody production</term><term>Antimalarial</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arthritic rats</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune disease</term><term>Bailey</term><term>Biochemical variables</term><term>Blood cells</term><term>Cancer patients</term><term>Carlson</term><term>Cell antibody production</term><term>Cell number</term><term>Cell response</term><term>Chloroquine</term><term>Clin</term><term>Clinical improvement</term><term>Clinical trials</term><term>Clinical variables</term><term>Clinics committee</term><term>Connolly</term><term>Control group</term><term>Cotton pellet granuloma</term><term>Crockson</term><term>Daily dose</term><term>Disease remission</term><term>Dmard</term><term>Dmard therapy</term><term>Dmards</term><term>Drug therapy</term><term>Drug treatment</term><term>Early stages</term><term>Effector</term><term>Effector cell function</term><term>Effector cells</term><term>Erythrocyte sedimentation rate</term><term>Experimental diet</term><term>Experimental group</term><term>Gold salts</term><term>Goldstein</term><term>Greater benefit</term><term>Haptene formation</term><term>Helper</term><term>Helper cell function</term><term>Helper cell proliferation</term><term>Helper cells</term><term>High incidence</term><term>High levels</term><term>Human model</term><term>Hydroxychloroquine</term><term>Ideal drug</term><term>Immune</term><term>Immune dysfunction</term><term>Immune response</term><term>Immune system</term><term>Immunol</term><term>Immunological</term><term>Immunological dysfunction</term><term>Immunomodulating activity</term><term>Immunomodulating drug therapy</term><term>Immunomodulatory activity</term><term>Inflammation</term><term>Inflammation research</term><term>Injectable gold</term><term>Joint destruction</term><term>Large numbers</term><term>Lupus erythematosus</term><term>Lymphocyte</term><term>Macrophage</term><term>Mcconkey</term><term>Medicinal chemistry</term><term>Normal host</term><term>Normal levels</term><term>Nsaid</term><term>Nutritional therapy</term><term>Patient populations</term><term>Percent gold</term><term>Peripheral blood</term><term>Peripheral blood leukocytes</term><term>Possible mechanisms</term><term>Previous examples</term><term>Proc</term><term>Prostaglandin</term><term>Raven press</term><term>Research institute</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Risk ratio</term><term>Scand</term><term>Side effects</term><term>Significant decrease</term><term>Splenic lymphocytes</term><term>Stecher</term><term>Sulphasalazine</term><term>Suppl</term><term>Suppressor</term><term>Suppressor cell</term><term>Suppressor cell proliferation</term><term>Suppressor cells</term><term>Suppressor response</term><term>Symptomatic relief</term><term>Therapeutic agent</term></keywords></textClass></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>suppressor</json:string><json:string>arthritis rheum</json:string><json:string>rheum</json:string><json:string>suppl</json:string><json:string>clin</json:string><json:string>stecher</json:string><json:string>macrophage</json:string><json:string>dmards</json:string><json:string>rheumatol</json:string><json:string>lymphocyte</json:string><json:string>dmard</json:string><json:string>clinical trials</json:string><json:string>immune</json:string><json:string>antirheumatic</json:string><json:string>antimalarial</json:string><json:string>helper cells</json:string><json:string>nsaid</json:string><json:string>immunol</json:string><json:string>effector</json:string><json:string>side effects</json:string><json:string>scand</json:string><json:string>crockson</json:string><json:string>immunological</json:string><json:string>proc</json:string><json:string>antibody production</json:string><json:string>rheumatoid</json:string><json:string>chloroquine</json:string><json:string>amer</json:string><json:string>prostaglandin</json:string><json:string>high levels</json:string><json:string>sulphasalazine</json:string><json:string>antirheumatic drugs</json:string><json:string>goldstein</json:string><json:string>mcconkey</json:string><json:string>hydroxychloroquine</json:string><json:string>connolly</json:string><json:string>suppressor cells</json:string><json:string>arthritis</json:string><json:string>rheumatoid arthritis</json:string><json:string>rheumatic diseases</json:string><json:string>drug therapy</json:string><json:string>human model</json:string><json:string>immune system</json:string><json:string>symptomatic relief</json:string><json:string>dmard therapy</json:string><json:string>inflammation</json:string><json:string>clinical variables</json:string><json:string>joint destruction</json:string><json:string>percent gold</json:string><json:string>control group</json:string><json:string>effector cells</json:string><json:string>therapeutic agent</json:string><json:string>experimental group</json:string><json:string>splenic lymphocytes</json:string><json:string>arthritic rats</json:string><json:string>suppressor cell proliferation</json:string><json:string>gold salts</json:string><json:string>suppressor cell</json:string><json:string>carlson</json:string><json:string>helper</json:string><json:string>immunomodulating activity</json:string><json:string>immunological dysfunction</json:string><json:string>autoimmune disease</json:string><json:string>daily dose</json:string><json:string>peripheral blood leukocytes</json:string><json:string>significant decrease</json:string><json:string>immune dysfunction</json:string><json:string>adverse effects</json:string><json:string>normal host</json:string><json:string>cell response</json:string><json:string>disease remission</json:string><json:string>cell antibody production</json:string><json:string>large numbers</json:string><json:string>peripheral blood</json:string><json:string>blood cells</json:string><json:string>normal levels</json:string><json:string>haptene formation</json:string><json:string>lupus erythematosus</json:string><json:string>helper cell proliferation</json:string><json:string>suppressor response</json:string><json:string>helper cell function</json:string><json:string>effector cell function</json:string><json:string>cotton pellet granuloma</json:string><json:string>cell number</json:string><json:string>immunomodulatory activity</json:string><json:string>previous examples</json:string><json:string>experimental diet</json:string><json:string>high incidence</json:string><json:string>erythrocyte sedimentation rate</json:string><json:string>drug treatment</json:string><json:string>clinics committee</json:string><json:string>clinical improvement</json:string><json:string>biochemical variables</json:string><json:string>injectable gold</json:string><json:string>patient populations</json:string><json:string>immune response</json:string><json:string>acylator phenotype</json:string><json:string>research institute</json:string><json:string>medicinal chemistry</json:string><json:string>possible mechanisms</json:string><json:string>immunomodulating drug therapy</json:string><json:string>american association</json:string><json:string>ideal drug</json:string><json:string>nutritional therapy</json:string><json:string>inflammation research</json:string><json:string>raven press</json:string><json:string>early stages</json:string><json:string>risk ratio</json:string><json:string>greater benefit</json:string><json:string>cancer patients</json:string><json:string>bailey</json:string></teeft></keywords><author><json:item><name>Vera J. Stecher</name><affiliations><json:string>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</json:string></affiliations></json:item><json:item><name>John A. Carlson</name><affiliations><json:string>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</json:string></affiliations></json:item><json:item><name>Kevin M. Connolly</name><affiliations><json:string>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</json:string></affiliations></json:item><json:item><name>Denis M. Bailey</name><affiliations><json:string>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</json:string></affiliations></json:item></author><articleId><json:string>MED2610050305</json:string></articleId><arkIstex>ark:/67375/WNG-MZ63XPTD-4</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>7.012</score><pdfWordCount>9944</pdfWordCount><pdfCharCount>57643</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>20</pdfPageCount><pdfPageSize>468 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>1</abstractWordCount><abstractCharCount>0</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Disease‐modifying antirheumatic drugs</title><pmid><json:string>3894835</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Medicinal Research Reviews</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1098-1128</json:string></doi><issn><json:string>0198-6325</json:string></issn><eissn><json:string>1098-1128</json:string></eissn><publisherId><json:string>MED</json:string></publisherId><volume>5</volume><issue>3</issue><pages><first>371</first><last>390</last><total>20</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Article</value></json:item></subject></host><namedEntities><unitex><date><json:string>1985</json:string></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Denis</json:string><json:string>A. Drugs</json:string><json:string>Kevin M. Connolly</json:string><json:string>John A. Carlson</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-MZ63XPTD-4</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string><json:string>2 - chemistry, medicinal</json:string></wos><scienceMetrix><json:string>1 - natural sciences</json:string><json:string>2 - chemistry</json:string><json:string>3 - medicinal & biomolecular chemistry</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Drug Discovery</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus></categories><publicationDate>1985</publicationDate><copyrightDate>1985</copyrightDate><doi><json:string>10.1002/med.2610050305</json:string></doi><id>1A3F5E9D74FA16125C32AD312F886727A964F8D4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Disease‐modifying antirheumatic drugs</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><licence>Copyright © 1985 Wiley Periodicals, Inc., A Wiley Company</licence></availability><date type="published" when="1985-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Disease‐modifying antirheumatic drugs</title><title level="a" type="short" xml:lang="en">ANTIRHEUMATIC DRUGS</title><author xml:id="author-0000"><persName><forename type="first">Vera J.</forename><surname>Stecher</surname></persName><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144<address><country key="US"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">John A.</forename><surname>Carlson</surname></persName><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144<address><country key="US"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Kevin M.</forename><surname>Connolly</surname></persName><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144<address><country key="US"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Denis M.</forename><surname>Bailey</surname></persName><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144<address><country key="US"></country></address></affiliation></author><idno type="istex">1A3F5E9D74FA16125C32AD312F886727A964F8D4</idno><idno type="ark">ark:/67375/WNG-MZ63XPTD-4</idno><idno type="DOI">10.1002/med.2610050305</idno><idno type="unit">MED2610050305</idno><idno type="toTypesetVersion">file:MED.MED2610050305.pdf</idno></analytic><monogr><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="pISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><idno type="book-DOI">10.1002/(ISSN)1098-1128</idno><idno type="book-part-DOI">10.1002/med.v5:3</idno><idno type="product">MED</idno><imprint><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="371">371</biblScope><biblScope unit="page" to="390">390</biblScope><biblScope unit="page-count">20</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1985-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords rend="articleCategory"><term>Article</term></keywords><keywords rend="tocHeading1"><term>Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1098-1128</doi><issn type="print">0198-6325</issn><issn type="electronic">1098-1128</issn><idGroup><id type="product" value="MED"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MEDICINAL RESEARCH REVIEWS">Medicinal Research Reviews</title><title type="short">Med. Res. Rev.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/med.v5:3</doi><numberingGroup><numbering type="journalVolume" number="5">5</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1985-07">July/September 1985</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="5" status="forIssue"><doi origin="wiley" registered="yes">10.1002/med.2610050305</doi><idGroup><id type="unit" value="MED2610050305"></id></idGroup><countGroup><count type="pageTotal" number="20"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="publisher">Copyright © 1985 Wiley Periodicals, Inc., A Wiley Company</copyright><eventGroup><event type="firstOnline" date="2006-09-18"></event><event type="publishedOnlineFinalForm" date="2006-09-18"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">371</numbering><numbering type="pageLast">390</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:MED.MED2610050305.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="216"></count></countGroup><titleGroup><title type="main" xml:lang="en">Disease‐modifying antirheumatic drugs</title><title type="short" xml:lang="en">ANTIRHEUMATIC DRUGS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Vera J.</givenNames><familyName>Stecher</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>John A.</givenNames><familyName>Carlson</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kevin M.</givenNames><familyName>Connolly</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Denis M.</givenNames><familyName>Bailey</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</unparsedAffiliation></affiliation></affiliationGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Disease‐modifying antirheumatic drugs</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ANTIRHEUMATIC DRUGS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Disease‐modifying antirheumatic drugs</title></titleInfo><name type="personal"><namePart type="given">Vera J.</namePart><namePart type="family">Stecher</namePart><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John A.</namePart><namePart type="family">Carlson</namePart><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kevin M.</namePart><namePart type="family">Connolly</namePart><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Denis M.</namePart><namePart type="family">Bailey</namePart><affiliation>Sterling‐Winthrop Research Institute, Rensselaer, New York 12144</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1985-07</dateIssued><copyrightDate encoding="w3cdtf">1985</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent><extent unit="references">216</extent></physicalDescription><relatedItem type="host"><titleInfo><title>Medicinal Research Reviews</title></titleInfo><titleInfo type="abbreviated"><title>Med. Res. Rev.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Article</topic></subject><identifier type="ISSN">0198-6325</identifier><identifier type="eISSN">1098-1128</identifier><identifier type="DOI">10.1002/(ISSN)1098-1128</identifier><identifier type="PublisherID">MED</identifier><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>371</start><end>390</end><total>20</total></extent></part></relatedItem><identifier type="istex">1A3F5E9D74FA16125C32AD312F886727A964F8D4</identifier><identifier type="ark">ark:/67375/WNG-MZ63XPTD-4</identifier><identifier type="DOI">10.1002/med.2610050305</identifier><identifier type="ArticleID">MED2610050305</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1985 Wiley Periodicals, Inc., A Wiley Company</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1A3F5E9D74FA16125C32AD312F886727A964F8D4
|texte= Disease‐modifying antirheumatic drugs
}}
| This area was generated with Dilib version V0.6.33. |  |